In this workshop, Mark Stewart, PhD, Vice President, Science Policy at Friends of Cancer Research, discusses Friends™ efforts to standardize TMB measurements to ensure clinically-meaningful results, and SeraCare™'s contributions to the project as the sole provider of TMB reference standards to Friends™ TMB Harmonization Working Group
Harmonization of methods to quantify tumor mutational burden (TMB) will facilitate robust biomarker development and optimize clinical utilization and treatment decision-making. Friends aims to better understand the impact of assay variation on clinical outcomes, align standards, and define best practices for TMB assessment.
Offered Free by: LGC SeraCare Life Sciences
See All Resources from: LGC SeraCare Life Sciences